BioCryst Pharmaceuticals | BCRX - Interest Expense On Debt


BioCryst Pharmaceuticals reported $14.14M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Alnylam Pharmaceuticals USD 69.29M 60.05M Mar/2026
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
Chugai Pharma JPY 95M 260M Dec/2025
Daiichi Sankyo JPY 2.16B 1.33B Dec/2025
DBV Technologies USD 461K 323.71K Mar/2025
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Gilead Sciences USD 240M 15M Mar/2026
GlaxoSmithKline GBP 167M 21M Mar/2026
Glaxosmithkline GBP 192.73M 14.79M Mar/2026
Incyte USD 569K 13K Mar/2026
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novavax USD 5.82M 342K Dec/2025
PTC Therapeutics USD 2.87B 2.82B Mar/2026
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
Ultragenyx Pharmaceutical USD 21M 2M Mar/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025